Skip to main content
. 2023 Aug 30;30(9):7984–8004. doi: 10.3390/curroncol30090580

Table 6.

Pharmaceutical antineoplastic expenditure in the population of breast cancer patients grouped by molecular intrinsic subtypes during the study period 2010–2019.

Molecular Intrinsic
Subtypes
Pharmaceutical
Expenditure
% Expenditure Patients % Patients Median Cost per Patient
(25th–75th Percentile)
HER2+ €28,126,333 82 767 33 €25,105 (€18,115 to €34.058)
Luminal €5,161,780 15 1197 52 €198 (€135 to 3348)
Triple negative €1,044,097 3 344 15 €314 (€154 to 3051)